, Papers of special note have been highlighted as either of interest (?) or of considerable interest (??) to readers
Improved survival in multiple myeloma and the impact of novel therapies, Blood, vol.111, issue.5, pp.2516-2520, 2008. ,
DOI : 10.1182/blood-2007-10-116129
Multiple Myeloma: From Front-Line to Relapsed Therapies, American Society of Clinical Oncology Educational Book, vol.35, pp.504-511, 2015. ,
DOI : 10.14694/EdBook_AM.2015.35.e504
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study, Leukemia, vol.16, issue.1, pp.149-157, 2012. ,
DOI : 10.1182/blood-2006-08-040410
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu, Blood, vol.112, issue.4, pp.1329-1337, 2008. ,
DOI : 10.1182/blood-2007-08-107292
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma, Molecular Cancer Therapeutics, vol.8, issue.9, pp.2616-2624, 2009. ,
DOI : 10.1158/1535-7163.MCT-09-0483
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM, Blood, vol.127, issue.23, pp.2833-2840, 2016. ,
DOI : 10.1182/blood-2016-01-694604
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b???2 dose-escalation study, The Lancet Haematology, vol.2, issue.12, pp.516-527, 2015. ,
DOI : 10.1016/S2352-3026(15)00197-0
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma, New England Journal of Medicine, vol.373, issue.7, pp.621-631, 2015. ,
DOI : 10.1056/NEJMoa1505654
Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology, Physiological Reviews, vol.88, issue.3, pp.841-886, 2008. ,
DOI : 10.1002/eji.1830240532
, ? This paper reviews the different functions of CD38
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond, Immunological Reviews, vol.124, issue.1, pp.95-112, 2016. ,
DOI : 10.1034/j.1399-0039.2003.00037.x
Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma, American Journal of Clinical Pathology, vol.121, issue.4, pp.482-488, 2004. ,
DOI : 10.1309/74R4TB90BUWH27JX
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors, The Journal of Immunology, vol.186, issue.3, pp.1840-1848, 1950. ,
DOI : 10.4049/jimmunol.1003032
, ? This paper describes the preclinic activity of daratumumab on myeloma cells
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma, mAbs, vol.120, issue.2, pp.311-321, 2015. ,
DOI : 10.1126/science.7973652
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fc?? Receptor???Mediated Cross-Linking, The Journal of Immunology, vol.114, issue.17, pp.807-813, 1950. ,
DOI : 10.1182/blood-2009-05-220285
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma, Blood, vol.128, issue.3, pp.384-394, 2016. ,
DOI : 10.1182/blood-2015-12-687749
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma, Clinical Cancer Research, vol.23, issue.15, 2017. ,
DOI : 10.1158/1078-0432.CCR-16-3192
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib, Clinical Cancer Research, vol.21, issue.12, pp.2802-2810, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-1813
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma, New England Journal of Medicine, vol.373, issue.13, pp.1207-1219, 2015. ,
DOI : 10.1056/NEJMoa1506348
, ? This paper presents the results of the phase 1 dose-escalation cohort evaluating daratumumab single agent in relapsed myeloma patients
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial, The Lancet, vol.387, issue.10027, pp.1551-1560, 2016. ,
DOI : 10.1016/S0140-6736(15)01120-4
, ?? This paper presents the results of the phase 1?2 evaluating daratumumab single agent in advanced relapsed myeloma patients
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma, Blood, vol.128, issue.14, 2016. ,
DOI : 10.1182/blood-2016-07-726729
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma, Blood, vol.128, issue.1, 2016. ,
DOI : 10.1182/blood-2016-03-705210
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma, Blood, vol.128, issue.7, pp.959-970, 2016. ,
DOI : 10.1182/blood-2016-03-703439
Daratumumab in combination with dexamethasone in resistant or refractory multiple myeloma: primary results of the IFM2014-04 Trial, Blood, vol.128, issue.22, pp.2138-2138, 2016. ,
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma, New England Journal of Medicine, vol.375, issue.14, pp.1319-1331, 2016. ,
DOI : 10.1056/NEJMoa1607751
, ?? This paper presents the results of the phase 3 trial demonstrating the superiority of the triplet daratumumab?lenalidomide? dexamethasone over lenalidomide -dexamethasone in relapsed myeloma patients
Efficacy of daratumumab , lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for relapsed or refractory multiple myeloma among patients with 1 to 3 prior lines of therapy based on previous treatment exposure: updated analysis of pollux, Blood, vol.128, issue.22, pp.489-489, 2016. ,
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma, New England Journal of Medicine, vol.375, issue.8, pp.754-766, 2016. ,
DOI : 10.1056/NEJMoa1606038
, ?? This paper presents the results of the phase 3 trial demonstrating the superiority of the triplet daratumumab?bortezomib? dexamethasone over bortezomib?dexamethasone in relapsed myeloma patients
Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of castor, Blood, vol.128, issue.22, pp.1150-1150, 2016. ,
Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone, Blood, vol.128, issue.22, pp.246-246, 2016. ,
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma, JAMA Oncology, vol.3, issue.1, pp.28-35, 2017. ,
DOI : 10.1001/jamaoncol.2016.3160
When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy, Transfusion, vol.39, issue.6pt2, pp.1555-1562, 2015. ,
DOI : 10.1046/j.1537-2995.1999.39070763.x
Resolving the daratumumab interference with blood compatibility testing, Transfusion, vol.268, issue.Suppl 15, pp.1545-1554, 2015. ,
DOI : 10.1126/scisignal.2002700
International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing, Transfusion, vol.55, issue.12, pp.2964-2972, 2016. ,
DOI : 10.1111/trf.13267
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma, Drugs, vol.100, issue.1, pp.853-867, 2016. ,
DOI : 10.3324/haematol.2014.107714
Abstract, Clinical Chemistry and Laboratory Medicine (CCLM), vol.5, issue.6, pp.1105-1109, 2016. ,
DOI : 20152126602
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, The Lancet Oncology, vol.17, issue.8, pp.328-346, 2016. ,
DOI : 10.1016/S1470-2045(16)30206-6
Clinical efficacy of daratumumab , pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among refractory patients, Blood, vol.128, issue.22, pp.492-492, 2016. ,
Open-label, multicenter, dose escalation Phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple Myeloma (PAVO), Blood, vol.128, issue.22, pp.1149-1149, 2016. ,
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group, Leukemia, vol.3, issue.4, pp.780-791, 2013. ,
DOI : 10.1056/NEJMoa1114083
Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple Myeloma, Blood, vol.128, issue.22, pp.2111-2111, 2016. ,
Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 monoclonal antibody isatuximab in Multiple Myeloma (MM), Blood, vol.128, issue.22, pp.2105-2105, 2016. ,
Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM), Clinical Lymphoma Myeloma and Leukemia, vol.17, issue.1, pp.2123-2123, 2016. ,
DOI : 10.1016/j.clml.2017.03.028
A Phase I/IIa study of the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma, Blood, vol.128, issue.22, pp.1152-1152, 2016. ,